新辅助化疗肿瘤细胞减灭术治疗晚期卵巢癌的临床意义被引量：4

导出

摘要目的探讨新辅助化疗结合中间性肿瘤细胞减灭术治疗晚期卵巢癌的临床意义。方法回顾性分析40例晚期卵巢癌患者，按照新辅助化疗后再减瘤和直接手术减瘤分为两组，比较化疗疗效和预后。结果新辅助化疗组化疗有效率88．9％，新辅助化疗组平均术中出血量明显少于直接手术组（P〈0．05）；新辅助化疗组手术时间较直接手术组缩短，两组比较有显著性差异（P〈0．05）。新辅助化疗组满意减瘤率为83．3％，明显高于直接手术组45．5％（P〈0．05）。新辅助化疗组和直接手术组中位生存时间分别为35个月和28个月，差异无统计学意义（P〉0．05）。结论新辅助化疗结合中间性肿瘤细胞减灭术可以明显提高晚期卵巢癌患者手术满意率，但并未延长患者生存期。 Objective To study the clinical significance of neoadjuvant chemotherapy combining with interval cytoreductive surgery for advanced ovarian cancer.Methods 40 patients with advanced ovarian cancer were analyzed retrospectively, and were divided into two groups according to whether they had received neoadjuvant chemotherapy or not before operation, the effect of chemotherapy and prognostic factors were analyzed. Results The response rate of chemotherapy was88.9%;The amount of bleeding and time of operation in neoadjuvant chemotherapy group was significantly less than those of without neoadjuvant chemotherapy group;The optimal cytoreductive surgery rate in neoadjuvant chemotherapy group was 83.3%,which was significantly higher than that of without neoadjuvant chemotherapy group（45.5%）;The median survival time of NACT group （35months） was longer than that of control group （28months）;there were no statistically significant differences between two groups in survival rate.Conclusions Neoadjuvant chemotherapy combining with interval cytoreductive surgery for advanced ovarian cancer can obviously improve the operation rate of satisfaction, but does not prolong survival period

作者成莉邢辉

机构地区湖北文理学院附属襄阳市中心医院

出处《浙江临床医学》 2013年第9期1284-1286,共3页 Zhejiang Clinical Medical Journal

基金湖北省卫生厅青年科技人才基金项目（QJX2008-61）

关键词新辅助化疗晚期卵巢癌中间性肿瘤细胞减灭术 Neoadjuvant chemotherapy Advanced ovarian cancer Interval cytoreductive surgery

分类号 R737.31 [医药卫生—肿瘤]

引文网络
相关文献

参考文献8

1Fotopou lou C Savvatis K Primary Radical Surgery in Elderly Patients With Epithelial Ovarian Cancer Analysis of Surgical Outcome and Long-Term Survival.lnt J Gynecol Cancer,2010,20(1):34-40.
2Heintz AP, Odicino F, Maisonneuve P, etal. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. IntJ Gynaecol Obstet, 2006, 95: 161-192.
3Tracey EA, Roder DM. Reasons for Improved Survival From Ovarian Cancer in New South Wales, Australia, Between 198(1 and 2003 Implications for Cancer Control. lnt J Gynecol Cancer, 2009, 19(4): 591-599.
4胡婷,张国楠.中间性肿瘤细胞减灭术在晚期卵巢上皮性癌中的治疗价值[J].实用妇产科杂志,2010,26(10):743-746. 被引量：2
5Deo C, Goyal H, Shukla NK, et ah Neoadjuvant chemotherapy followed by surgical cytoreduction in advanced epithelial ovarian cancer. Indian JCancer, 2006, 43(3): 117-121.
6Hou JY, Kelly MG, Yu H, etal. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecologic Oncology, 2007, 105(1): 211-217.
7Lee SJ,KIM BG,Lee JW, etal. Preliminary results of neoadjuvant chemotherapy with paclitaxeland cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.J Obstet Gynaecol P, es,2006,32(1):99-106.
8Hou JY, Kelly MG, Yu H,etal. Neoadjuvantchem otherapy lessens surgicalm orbidity in advanced ovarian cancer and leads to im proved survivalin stagelVdisease.GynecolOncol,2007, 105(1): 211-217.

二级参考文献1

1Tien Le MD, FRCSC,Ghadeer Alshaikh MD, FRCSC,Laura Hopkins MD, FRCSC,Wylam Faught MD, FRCSC,Michael Fung Kee Fung MB, FRCSC. Prognostic Significance of Postoperative Morbidities in Patients With Advanced Epithelial Ovarian Cancer Treated With Neoadjuvant Chemotherapy and Delayed Primary Surgical Debulking[J] 2006,Annals of Surgical Oncology(12):1711～1716